{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-039793","form_type":"8-K","ticker":"CTMX","cik":"0001501989","company_name":"CytomX Therapeutics, Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.121551+00:00","generated_at":"2026-06-12T01:40:46.302957+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CytomX Q2 revenue $24.7M (up 91% YoY); cash runway into H2 2025 after $30M financing","bullets":["Cash, equivalents & investments $180.9M at June 30, 2023; $30M gross financing from BVF closed July 2023.","Revenue $24.7M (vs $12.9M Q2 2022) driven by BMS collaboration; R&D expenses fell to $20.7M.","CX-904 (EGFRxCD3) Phase 1 dose escalation data anticipated first half of 2024; backfill cohorts by end 2023.","IND filings for wholly-owned CX-2051 (EpCAM ADC) and CX-801 (IFNa2b) expected Q4 2023.","Appointed Dr. Wayne Chu as CMO; promoted Dawn Benson to SVP Quality and Product Manufacturing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-039793","json":"https://secwatch.observer/filing/0000950170-23-039793.json","markdown":"https://secwatch.observer/filing/0000950170-23-039793.md","text":"https://secwatch.observer/filing/0000950170-23-039793.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501989/000095017023039793/0000950170-23-039793-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501989/000095017023039793/ctmx-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T01:40:46.302957+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"052e1b9c1992b2925fdceb3dd7c7a5d0b84340d4","claim":"CytomX Therapeutics, Inc. reported financial results for second quarter 2023.","evidence_excerpt":"On August 8, 2023, CytomX Therapeutics, Inc., a Delaware corporation (the “Company”) issued a press release reporting its unaudited financial results as of and for the three and six months ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501989/000095017023039793/0000950170-23-039793-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}